Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases in prostate cancer survivors with hormone-refractory prostate cancer (HRPC). The announcement of the trial follows a successful end-of-phase II meeting with the US Food and Drug Administration (FDA).

This trial is all ready been on-going since June 2008 in Europe. Recruitment of US survivors into the study is now planned to commence this year. They anticipate enrolling 750 HRPC patients with bone metastases.

In the phase II trials, Alpharadin demonstrated strong evidence that it can prolong patient survival times, improves quality of life and offers a placeb